← Back to Search

Antibody

MEDI1341 for Parkinson's Disease

Phase 1
Waitlist Available
Led By Beth E. Safirstein, MD
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 weeks

Summary

This trial tests MEDI1341, a drug given through an injection, in people with Parkinson's Disease. The goal is to see if it can help improve movement and reduce symptoms. Participants will receive the treatment multiple times over a few months, and the study will last several months per person.

Eligible Conditions
  • Parkinson's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adverse Events
Body Weight
Impaired cognition
+7 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MEDI1341Experimental Treatment1 Intervention
3 doses given at 4 week intervals
Group II: PlaceboPlacebo Group1 Intervention
3 doses given at 4 week intervals
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MEDI1341
2020
Completed Phase 1
~80

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,397 Previous Clinical Trials
289,121,631 Total Patients Enrolled
TakedaIndustry Sponsor
1,238 Previous Clinical Trials
4,149,142 Total Patients Enrolled
Beth E. Safirstein, MDPrincipal InvestigatorMD Clinical
1 Previous Clinical Trials
67 Total Patients Enrolled
~5 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top